Stemline Therapeutics (STML) Announces Presentation of SL-401 Phase 2 Data in AML;
Tweet Send to a Friend
Stemline Therapeutics, Inc. (Nasdaq: STML) announced the presentation of SL-401 lead-in data from its ongoing Phase 2 trial in acute ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
